Literature DB >> 15553802

Venous access port-related nocardia bacteremia with successful short-term antibiotics treatment.

Yin-Hsun Feng1, Wen-Tsung Huang, Chao-Jung Tsao.   

Abstract

Nocardia infection occurs primarily among patients with deficient cell-mediated immunity. The portal of entry in the majority of patients with Nocardia infection is pulmonary origin. Central venous catheter-associated bacteremia caused by Nocardia species is very rare, and the optimal management for these situations was indeterminate. Most patients were cured after discontinuation of central venous catheter and prolonged antibiotics use. Thereafter, we reported an 18-year-old male who received chemotherapy for his nasal rhabdomyosarcoma had central venous catheter-associated N. asteroids bacteremia. The outcome was satisfying after discontinuation of central venous catheter followed by short-term antibiotics. Conclusively, prolonged antibiotics may not be necessary in catheter-associated Nocardia bacteremia without distant metastatic site after removal of catheter.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15553802

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  3 in total

1.  Catheter-associated Nocardia higoensis bacteremia in a child with acute lymphocytic leukemia.

Authors:  Michael E Watson; Michele M Estabrook; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2010-11-17       Impact factor: 5.948

Review 2.  Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy.

Authors:  Barbara A Brown-Elliott; June M Brown; Patricia S Conville; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

3.  The first case of catheter-related bloodstream infection caused by Nocardia farcinica.

Authors:  Sang Taek Heo; Kwan Soo Ko; Ki Tae Kwon; Seong Yeol Ryu; In Gyu Bae; Won Sup Oh; Jae-Hoon Song; Kyong Ran Peck
Journal:  J Korean Med Sci       Date:  2010-10-26       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.